{"id":"https://openalex.org/W2138167692","doi":"https://doi.org/10.1111/ejh.12264","title":"Cost\u2010effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population\u2010based study","display_name":"Cost\u2010effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population\u2010based study","publication_year":2014,"publication_date":"2014-01-09","ids":{"openalex":"https://openalex.org/W2138167692","doi":"https://doi.org/10.1111/ejh.12264","mag":"2138167692","pmid":"https://pubmed.ncbi.nlm.nih.gov/24400940"},"language":"en","primary_location":{"id":"doi:10.1111/ejh.12264","doi":"https://doi.org/10.1111/ejh.12264","is_oa":false,"landing_page_url":"https://doi.org/10.1111/ejh.12264","pdf_url":null,"source":{"id":"https://openalex.org/S159715054","display_name":"European Journal Of Haematology","issn_l":"0902-4441","issn":["0902-4441","1600-0609"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016822168","display_name":"Hedwig M. Blommestein","orcid":"https://orcid.org/0000-0002-5846-0531","observed_orcids":["https://orcid.org/0000-0002-5846-0531"]},"institutions":[{"id":"https://openalex.org/I913958620","display_name":"Erasmus University Rotterdam","ror":"https://ror.org/057w15z03","country_code":"NL","type":"education","lineage":["https://openalex.org/I913958620"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Hedwig M. Blommestein","raw_affiliation_strings":["Department of Health Policy & Management Institute for Medical Technology Assessment Erasmus University Rotterdam The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Policy & Management Institute for Medical Technology Assessment Erasmus University Rotterdam The Netherlands","institution_ids":["https://openalex.org/I913958620"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090601374","display_name":"Djamila E. Issa","orcid":"https://orcid.org/0000-0002-4512-7019","observed_orcids":["https://orcid.org/0000-0002-4512-7019"]},"institutions":[{"id":"https://openalex.org/I911458345","display_name":"Amsterdam UMC Location Vrije Universiteit Amsterdam","ror":"https://ror.org/00q6h8f30","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833","https://openalex.org/I911458345"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Djamila E. Issa","raw_affiliation_strings":["VU University Medical Center, Amsterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I911458345"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025387044","display_name":"Marjolein Pompen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087126","display_name":"Bristol-Myers Squibb (Netherlands)","ror":"https://ror.org/00354aw77","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210087126","https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210105140","display_name":"Roche (Netherlands)","ror":"https://ror.org/01gcg9888","country_code":"NL","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210105140"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Marjolein Pompen","raw_affiliation_strings":["Currently employed at Bristol-Myers Squibb, Woerden, The Netherlands","Roche Pharmaceuticals Woerden The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Currently employed at Bristol-Myers Squibb, Woerden, The Netherlands","institution_ids":["https://openalex.org/I4210087126"]},{"raw_affiliation_string":"Roche Pharmaceuticals Woerden The Netherlands","institution_ids":["https://openalex.org/I4210105140"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011491343","display_name":"Gerhard Ten Hoor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210105140","display_name":"Roche (Netherlands)","ror":"https://ror.org/01gcg9888","country_code":"NL","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210105140"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Gerhard Ten Hoor","raw_affiliation_strings":["Roche Pharmaceuticals, Woerden, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Pharmaceuticals, Woerden, The Netherlands","institution_ids":["https://openalex.org/I4210105140"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027058055","display_name":"Mels Hoogendoorn","orcid":"https://orcid.org/0000-0001-8032-2592","observed_orcids":["https://orcid.org/0000-0001-8032-2592"]},"institutions":[{"id":"https://openalex.org/I2802652803","display_name":"Medisch Centrum Leeuwarden","ror":"https://ror.org/0283nw634","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802652803","https://openalex.org/I4405259012"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Mels Hogendoorn","raw_affiliation_strings":["Medical Center Leeuwarden Leeuwarden The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Center Leeuwarden Leeuwarden The Netherlands","institution_ids":["https://openalex.org/I2802652803"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110068950","display_name":"Peter Joosten","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802652803","display_name":"Medisch Centrum Leeuwarden","ror":"https://ror.org/0283nw634","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802652803","https://openalex.org/I4405259012"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Peter Joosten","raw_affiliation_strings":["Medical Center Leeuwarden Leeuwarden The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Center Leeuwarden Leeuwarden The Netherlands","institution_ids":["https://openalex.org/I2802652803"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083385949","display_name":"Sonja Zweegman","orcid":"https://orcid.org/0000-0002-5011-1820","observed_orcids":["https://orcid.org/0000-0002-5011-1820"]},"institutions":[{"id":"https://openalex.org/I911458345","display_name":"Amsterdam UMC Location Vrije Universiteit Amsterdam","ror":"https://ror.org/00q6h8f30","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833","https://openalex.org/I911458345"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Sonja Zweegman","raw_affiliation_strings":["VU University Medical Center, Amsterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I911458345"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112976340","display_name":"Peter C. Huijgens","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I911458345","display_name":"Amsterdam UMC Location Vrije Universiteit Amsterdam","ror":"https://ror.org/00q6h8f30","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833","https://openalex.org/I911458345"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Peter C. Huijgens","raw_affiliation_strings":["VU University Medical Center, Amsterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I911458345"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038426869","display_name":"Carin A. Uyl\u2010de Groot","orcid":"https://orcid.org/0000-0001-5808-302X","observed_orcids":["https://orcid.org/0000-0001-5808-302X"]},"institutions":[{"id":"https://openalex.org/I913958620","display_name":"Erasmus University Rotterdam","ror":"https://ror.org/057w15z03","country_code":"NL","type":"education","lineage":["https://openalex.org/I913958620"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Carin A. Uyl\u2010de Groot","raw_affiliation_strings":["Department of Health Policy & Management Institute for Medical Technology Assessment Erasmus University Rotterdam The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Policy & Management Institute for Medical Technology Assessment Erasmus University Rotterdam The Netherlands","institution_ids":["https://openalex.org/I913958620"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5016822168"],"corresponding_institution_ids":["https://openalex.org/I913958620"],"apc_list":{"value":4650,"currency":"USD","value_usd":4650},"apc_paid":null,"fwci":7.5033,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.96778639,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"92","issue":"5","first_page":"398","last_page":"406"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8467000126838684,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8467000126838684,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.12070000171661377,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.009700000286102295,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9089999794960022},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/relapsed-follicular-lymphoma","display_name":"relapsed follicular lymphoma","score":0.9850000143051147},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9359999895095825},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.7860000133514404},{"id":"https://openalex.org/keywords/cost-per-life-year-gained","display_name":"cost per life-year gained","score":0.8299999833106995},{"id":"https://openalex.org/keywords/second-line-chemotherapy","display_name":"second-line chemotherapy","score":0.8259999752044678},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.6190000176429749},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.7179999947547913},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.4560000002384186},{"id":"https://openalex.org/keywords/healthcare-decision-making","display_name":"healthcare decision-making","score":0.47600001096725464}],"concepts":[{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.8673365116119385},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7564700245857239},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.7291353344917297},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.6091465950012207},{"id":"https://openalex.org/C3020493868","wikidata":"https://www.wikidata.org/wiki/Q55631277","display_name":"Real world data","level":2,"score":0.5274232625961304},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.522736132144928},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.4877384603023529},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4523632228374481},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4207664728164673},{"id":"https://openalex.org/C17923572","wikidata":"https://www.wikidata.org/wiki/Q7250160","display_name":"Propensity score matching","level":2,"score":0.4100992977619171},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3847789466381073},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.24060624837875366},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.07640686631202698},{"id":"https://openalex.org/C2522767166","wikidata":"https://www.wikidata.org/wiki/Q2374463","display_name":"Data science","level":1,"score":0.0},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008224","descriptor_name":"Lymphoma, Follicular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008224","descriptor_name":"Lymphoma, Follicular","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D008224","descriptor_name":"Lymphoma, Follicular","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009426","descriptor_name":"Netherlands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012042","descriptor_name":"Registries","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1111/ejh.12264","doi":"https://doi.org/10.1111/ejh.12264","is_oa":false,"landing_page_url":"https://doi.org/10.1111/ejh.12264","pdf_url":null,"source":{"id":"https://openalex.org/S159715054","display_name":"European Journal Of Haematology","issn_l":"0902-4441","issn":["0902-4441","1600-0609"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:24400940","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24400940","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of haematology","raw_type":"Journal Article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/f4ba0a06-2683-433d-b25e-8700ea4121df","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/f4ba0a06-2683-433d-b25e-8700ea4121df","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Blommestein, H M, Issa, D E, Pompen, M, Ten Hoor, G, Hogendoorn, M, Joosten, P, Zweegman, S, Huijgens, P C & Uyl-de Groot, C A 2014, 'Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study', European journal of haematology, vol. 92, no. 5, pp. 398-406. https://doi.org/10.1111/ejh.12264","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:vumc:oai:pure.atira.dk:publications/ecde2115-add7-4f10-a717-d1c3f0096c62","doi":null,"is_oa":false,"landing_page_url":"https://research.vumc.nl/en/publications/ecde2115-add7-4f10-a717-d1c3f0096c62","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"European Journal of Haematology, 92(5), 398 - 406. Wiley-Blackwell","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1972000000","https://openalex.org/W1997706755","https://openalex.org/W2001302091","https://openalex.org/W2021371817","https://openalex.org/W2052062395","https://openalex.org/W2063138322","https://openalex.org/W2101141816","https://openalex.org/W2101648653","https://openalex.org/W2106326841","https://openalex.org/W2108131857","https://openalex.org/W2127749132","https://openalex.org/W2141696964","https://openalex.org/W2142568359","https://openalex.org/W2143168735","https://openalex.org/W2150291618","https://openalex.org/W2154643481","https://openalex.org/W2156522119","https://openalex.org/W2157450846","https://openalex.org/W2159982513","https://openalex.org/W2169578616"],"related_works":["https://openalex.org/W2020558244","https://openalex.org/W2040282525","https://openalex.org/W1972000000","https://openalex.org/W2141696964","https://openalex.org/W2329092139","https://openalex.org/W1865067915","https://openalex.org/W2402826213","https://openalex.org/W2336585753","https://openalex.org/W2529044886","https://openalex.org/W2554151492"],"abstract_inverted_index":{"OBJECTIVES:":[0],"On":[1],"the":[2,13,39,42,93,98,241],"basis":[3],"of":[4,16,136,147,155,177,225,243],"two":[5,47],"population-based":[6,48],"registries,":[7],"our":[8],"study":[9],"aims":[10],"to":[11,31,55,79,89,232,239],"calculate":[12,56],"real-world":[14,73,99,152,166,189,196],"cost-effectiveness":[15,246],"rituximab":[17,100,210],"maintenance":[18],"compared":[19],"with":[20,129,219],"observation":[21,102],"in":[22,127,134,188],"relapsed":[23],"or":[24],"refractory":[25],"follicular":[26],"lymphoma":[27],"patients":[28,74],"who":[29],"responded":[30],"second-line":[32,90,107],"chemotherapy.":[33],"METHODS:":[34],"Data":[35],"were":[36,75,104,113,163,193],"obtained":[37],"from":[38,202],"EORTC20981":[40],"trial,":[41],"Netherlands":[43],"Cancer":[44],"Registry":[45],"and":[46,63,83,101,109,140,150,159,173,181,190,223],"registries.":[49],"A":[50],"Markov":[51],"model":[52],"was":[53],"developed":[54],"cost":[57,131],"per":[58,138,142,157,161,179,183],"life":[59,65],"year":[60],"gained":[61],"(LYG)":[62],"quality-adjusted":[64],"years":[66,81],"(QALYs)":[67],"for":[68,106,170,209],"three":[69],"scenarios.":[70,247],"RESULTS:":[71],"Our":[72],"(62":[76],"years)":[77],"6":[78],"7":[80],"older":[82],"had":[84],"higher":[85],"complete":[86],"response":[87],"rates":[88],"chemotherapy":[91,108],"than":[92],"trial":[94,124,148,191,204],"population.":[95],"Differences":[96],"between":[97],"group":[103],"observed":[105],"disease":[110],"progression.":[111],"Groups":[112],"more":[114],"balanced":[115],"after":[116],"using":[117,195],"propensity":[118],"matching.":[119],"Relying":[120],"entirely":[121],"on":[122],"updated":[123],"results":[125,201,213],"(scenario1)":[126],"combination":[128],"local":[130],"data":[132,197,220],"resulted":[133],"ratios":[135,154,176],"\u20ac11,259":[137],"LYG":[139,158,180],"\u20ac12,655":[141],"QALY.":[143,184],"For":[144],"scenario2,":[145],"consisting":[146],"efficacy":[149],"matched":[151,167],"costs,":[153],"\u20ac21,202":[156],"\u20ac23,821":[160],"QALY":[162],"calculated.":[164],"Using":[165],"evidence":[168],"(scenario3)":[169],"both":[171],"effectiveness":[172],"costs":[174],"showed":[175,206,214],"\u20ac10,591":[178],"\u20ac11,245":[182],"CONCLUSION:":[185],"Although":[186],"differences":[187],"population":[192],"found,":[194],"as":[198,200],"well":[199],"long-term":[203],"follow-up":[205],"favourable":[207],"ICERs":[208],"maintenance.":[211],"Nevertheless,":[212],"that":[215],"caution":[216],"is":[217],"required":[218],"synthesis,":[221],"interpretation":[222],"generalisability":[224],"results.":[226],"As":[227],"different":[228,233],"scenarios":[229],"provide":[230],"answers":[231],"questions,":[234],"we":[235],"recommend":[236],"healthcare":[237],"decision-makers":[238],"recognise":[240],"importance":[242],"calculating":[244],"several":[245]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}